Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1 positive advanced non small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies (2019)
- Authors:
- Autor USP: CASTRO JUNIOR, GILBERTO DE - FM
- Unidade: FM
- DOI: 10.1016/j.lungcan.2019.07.004
- Subjects: NEOPLASIAS PULMONARES; CARCINOMA BRONCOGÊNICO; IMUNOTERAPIA; ANTICORPOS MONOCLONAIS
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Lung cancer
- ISSN: 0169-5002
- Volume/Número/Paginação/Ano: v. 135, p. 188-195, 2019
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
NOSAKI, Kaname et al. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1 positive advanced non small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung cancer, v. 135, p. 188-195, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.lungcan.2019.07.004. Acesso em: 04 out. 2024. -
APA
Nosaki, K., Saka, H., Hosomi, Y., Baas, P., Castro Junior, G. de C., Reck, M., et al. (2019). Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1 positive advanced non small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung cancer, 135, 188-195. doi:10.1016/j.lungcan.2019.07.004 -
NLM
Nosaki K, Saka H, Hosomi Y, Baas P, Castro Junior G de C, Reck M, Wu Y-L, Brahmer JR, Felip E, Sawada T. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1 positive advanced non small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies [Internet]. Lung cancer. 2019 ; 135 188-195.[citado 2024 out. 04 ] Available from: https://doi.org/10.1016/j.lungcan.2019.07.004 -
Vancouver
Nosaki K, Saka H, Hosomi Y, Baas P, Castro Junior G de C, Reck M, Wu Y-L, Brahmer JR, Felip E, Sawada T. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1 positive advanced non small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies [Internet]. Lung cancer. 2019 ; 135 188-195.[citado 2024 out. 04 ] Available from: https://doi.org/10.1016/j.lungcan.2019.07.004 - Diagnóstico de mutações ativadoras do gene EGFR em adenocarcinomas pulmonares: caracterização e implicações clínicas
- Efficacy and safety of ceritinib (450 mg/d or 600 mg/d) with food versus 750-mg/d fasted in patients with ALK receptor tyrosine kinase (ALK)-Positive NSCLC: primary efficacy results from the ASCEND-8 study
- Extraoral photobiomodulation for prevention of oral and oropharyngeal mucositis in head and neck cancer patients: interim analysis of a randomized, double-blind, clinical trial
- Manual de oncologia torácica
- Lung Cancer in Brazil [Editorial]
- Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: health-related quality-of-life results from KEYNOTE-048
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- Noções de oncologia torácica
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
- Pembrolizumab alone or with chemotherapy for recurrent/metastatic had and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed death Ligand-1 combined positive score
Informações sobre o DOI: 10.1016/j.lungcan.2019.07.004 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas